European Pharmaceutical Review
MARCH 12, 2024
Life science companies are increasingly using advanced technologies like artificial intelligence (AI), machine learning (ML) and blockchain to improve data quality and integrity by detecting anomalies in data and establishing tamper-proof audit trails for all data-related activities Data governance. How can this be mitigated?
Nixon Gwilt Law
APRIL 22, 2024
Its three separate Rules (Security, Privacy, and Breach) impose a variety of security controls, documentation, governance, and notice requirements on custodians of protected health information (PHI). The HTI-1 Final Rule is an AI disclosure and governance rule published by the US Department of Health and Human Services (HHS).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
OCTOBER 1, 2022
Sharing data across borders ensures access to safe tissues and cells for human application is ethical and supply quality is adequate, said the Council in a statement. When this is done, appropriate transplant supply needs can be met and adequate funding for tissue, cell and organ donation schemes can be identified.
Clarivate
JULY 21, 2022
If the research is used to inform policy decisions around, food safety and public health, for example, then misleading and false research can risk people’s lives. Ethical publishing: an introductory course. Share your knowledge around research ethics with your peers, for example by presenting a seminar at your institution.
PM360
JUNE 26, 2023
As shareholders and consumers demand greater transparency, accountability, and ethical behavior from corporations, pharmaceutical companies are expected to play a role in addressing these issues. These partnerships can be with local governments, healthcare providers, local startups, and non-governmental organizations.
Pharma Marketing Network
JULY 26, 2023
As new healthcare challenges arise and the pharmaceutical landscape evolves, the FDA may be allocating its resources to focus on other pressing issues, such as drug approvals, monitoring emerging health threats, and enhancing drug safety. The post Why Is FDA Issuing Fewer Marketing Violation Letters?
MedReps
SEPTEMBER 19, 2022
First, they’ll likely have more interest in learning about what you sell and second, they’ll be more hesitant to try it because of concerns about insurance coverage, efficacy and safety. Thanks to the mistakes of other companies, the landscape of rules and laws that govern how medical sales reps sell are constantly changing.
Expert insights. Personalized for you.
94 
Let's personalize your content